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Summary 1 
Objectives: The omega-3 (n-3) fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic 2 
acid (DHA), are known to play an important role in maintenance and modulation of neuronal 3 
functions. There is evidence that omega-3 fatty acids may have anticonvulsant effects.  The 4 
effect of DHA and EPA on seizure rate in patients with DRE was investigated.   5 
Methods: 6 
A double-blind, randomized, placebo-controlled clinical trial included ninety-nine (n=99) DRE 7 
subjects, aged 5-16 (n=85) and 17-45 (n=14). After randomization, subjects were given two, 8 
four or six capsules per day of DHA (417.8 mg DHA and 50.8 mg EPA/capsule, n=33), EPA 9 
(385.6 mg EPA and 81.2 mg DHA/capsule, n=33) or placebo (high oleic acid sunflower oil, 10 
n=33) for one year. The primary endpoint was the effect of treatment on rate of seizure.   11 
Random-effects negative binomial regression models were fitted to model the patients’ total 12 
count of seizures per month. The treatment effects on seizure incidence rate ratio was tested 13 
after controlling for the covariate effects of gender, age, rate of seizure per week at enrollment, 14 
type of seizure  and number of AEDs combinations used at enrollment. 15 
Results: 16 
Fifty-nine subjects (n=59) completed the study (59.6%).The average number of seizures per 17 
month were 9.7 ± 1.2 in the EPA group, 11.7 ± 1.5 in the DHA group, and 16.6 ± 1.5 in the 18 
placebo group. Age, gender and seizure type adjusted seizure incidence rate ratios (IRRs) of 19 
the EPA and DHA groups compared with the placebo were 0.61 (CI= 0.42-0.88, p=0.008, 42% 20 
reduction) and 0.67 (CI = 0.46-1.0, p= 0.04, 39% reduction), respectively. There was no 21 
difference in IRR between the EPA and DHA groups (p=0.56). Both treatment groups had a 22 
significantly higher number of seizure-free days compared to placebo (p<0.05).   23 
Ibrahim et al 
4 
 
Significance:  1 
This study demonstrates that EPA and DHA are effective in reducing seizure frequency in 2 
patients with DRE 3 
 4 
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Introduction 1 
Epileptic seizures are characterized by unpredictable abnormal electrical discharge and 2 
convulsions1. Epilepsy, the tendency to have recurrent unprovoked seizures2, affects over 50 3 
million people worldwide and accounts for about 1% of the global burden of disease 3.  Anti-4 
epileptic drugs (AEDs) are effective in reducing or eliminating seizures in the majority of 5 
patients with the condition. However, one third of the patients continue to have two or more 6 
seizures a month in spite of treatment with maximum therapeutic doses4.  Patients with drug-7 
resistant epilepsy (DRE) are managed with alternative treatments including  neurosurgery 5, 8 
neurostimulation,  and ketogenic and modified Atkins diets 5 with variable success.  Therefore, 9 
there is a need for an effective therapy for patients with DRE. 10 
The omega-3 (n-3) fatty acids, eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, are 11 
known to play a pivotal role in maintenance and modulation of neuronal functions6, 7, neuronal 12 
excitability8, cell signalling9, 10, inflammatory response11 and receptor function and release of 13 
neurotransmitters12. Moreover, studies have shown altered membrane lipid composition in 14 
various neuropsychiatric disorders 13. These findings have led to the postulation that treatment 15 
with DHA and EPA could ameliorate seizures in patients with DRE 14, 15. 16 
Ex vivo and animal studies have provided evidence that omega-3 fatty acids have 17 
anticonvulsant protection effects in several models tested16-20. In contrast, the findings of the 18 
clinical investigations have been equivocal, some demonstrated efficacy14, 21, 22 while others 19 
did not 15. These inconclusive outcomes of omega-3 trials in patients with DRE were attributed 20 
to a number of factors; chief among them are the dietary background of the subjects 23, selected 21 
dose, duration of the treatment, and the EPA/ DHA ratios 24, 25. Hence there is a need for more 22 
well- designed trials to help elucidate whether or not these fatty acids have the potential to 23 
ameliorate seizures in patients with the DRE.  24 
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In this study, we investigated the effect of DHA and EPA on seizure rates in patients with DRE.  1 
 2 
Subject and Methods 3 
Study design 4 
This study is a randomized, double-blind, placebo-controlled, parallel-group, clinical trial in 5 
patients with DRE. The participants were randomized to receive their respective treatments – 6 
EPA, DHA or placebo for one year – while kept on their regular AEDs during the intervention 7 
period. The study was conducted at Soba University Hospital Neurology Referral Clinic, Ibn-8 
Aoaf Pediatric Teaching Hospital Neurology Referral Clinics, Khartoum, Sudan. Approvals 9 
were obtained from the ethics committees of the Federal Ministry of Health of Sudan, the 10 
Faculty of Medicine, University of Khartoum, Sudan and London Metropolitan University, 11 
UK. Self- or investigator-read and explained written consent was obtained from the adult and 12 
parents or guardians of the underage participants. This study was conducted in accordance with 13 
the International Conference of Harmonization notes for Guidance on Good Clinical Practice, 14 
the principles of the Declaration of Helsinki as revised in 2007, the established methodological 15 
procedures according to the revised CONSORT statement. The study is registered with 16 
ISRCTN registry (ISRCTN57643242)  17 
Patients 18 
Ninety-nine (n=99) DRE patients, aged 5-16 (n=85) and 17-45 (n=14) who have been in regular 19 
follow-up at the aforementioned clinics were enrolled between June 2012 and December 2013. 20 
The subjects who consented to participate in the study were initially assessed for eligibility 21 
before invitation to attend the screening visit. The inclusion criteria were: 5 to 50 years old 22 
male or female patients with focal and generalized seizures, well-documented DRE in 23 
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accordance with the International League Against Epilepsy (ILAE) classification. DRE is 1 
defined as two or more seizures per month for three months prior to the screening visit despite 2 
treatment with two or more AEDs at optimal stable dosages for more than one month prior to 3 
screening. All patients underwent EEG examination as part of the clinical work-up. The 4 
exclusion criteria were: epilepsy due to metabolic causes, trauma or space occupying lesions, 5 
quadriplegic, ataxic and dyskinetic cerebral palsy, other chronic condition and regular intake 6 
of n-3 fatty acid supplement or inability to swallow capsules.   7 
Randomization and blinding  8 
The subjects, after stratification by age and gender, were randomly assigned to receive coded 9 
and indistinguishable high DHA, high EPA or placebo capsules. Randomization was 1:1:1 ratio 10 
conducted using a sequence of computer-generated random numbers at the Faculty of Life 11 
Sciences, London Metropolitan University (UK). It was performed by a  person who had no 12 
knowledge about demographic, clinical or laboratory characteristics of the patients, and staff 13 
of the referral clinics, investigators and participants were blinded until the biochemical and 14 
clinical outcome data were analyzed and the database unlocked.  15 
Efficacy assessment 16 
The primary endpoint was the difference in seizure rate between the treatment groups and 17 
placebo at the end of the intervention period. Secondary endpoints were the proportion of 18 
subjects with ≥25% reduction (response rate) in seizure rate compared to baseline and seizure-19 
free days over the treatment period. 20 
Safety assessment 21 
Adverse events were categorized as serious if they were life threatening, resulted in death, 22 
required inpatient hospitalization, gave rise to a significant disability and congenital birth 23 
defect. Hematology parameters, liver function and lipid profile were measured at baseline and 24 
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end of treatment. Past medical history, physical examination, vital signs, and body weight were 1 
recorded on a monthly basis by the investigators.     2 
Procedure 3 
Subsequent to randomization, the subjects were given daily, for one year, two (5-10 years old, 4 
median weight (mw)=25 kg), four (11-16 years old, mw=37 kg) or six (17-50 years old, mw=51 5 
kg) capsules of DHA (417.8 mg DHA and 50.8 mg EPA/capsule, n=33), EPA (385.6 mg EPA 6 
and 81.2 mg DHA/capsule, n=33) or placebo (high oleic acid sunflower seed oil, n=33). 7 
Omega-3 fatty acid dose was calculated by multiplying the median weight of each age group 8 
by 25 mg/kg body weight. Vitamin E (1.5 mg/capsule) was added to the three types of capsules 9 
to prevent peroxidation. Both types of capsules were carefully matched in appearance and 10 
flavor to prevent treatment unmasking. Enrollment identification number, gender, residence, 11 
ethnicity, weight, epilepsy clinical diagnosis, type of epileptic  seizure, number of seizures per 12 
month, the time when the patient was diagnosed with DRE, MRI findings, EEG findings,  13 
aetiology of the epileptic seizures and AEDs in use at enrollment were collected using a 14 
structured questionnaire at baseline. At baseline and each monthly follow-up visit, vital signs, 15 
history and physical examination were obtained.  A monthly patient-recorded daily health diary 16 
was given to each patient or their guardian to record seizure frequency on a daily basis, AEDs 17 
received, any additional medications, study drug intake, visit to heath facilities and 18 
hospitalization. Whole blood, about 10 ml, was obtained from the patients at baseline and end 19 
of the treatment visit (EOT) to analyze the complete blood count, liver function, glucose and 20 
lipid profile. Name and telephone number of the medical doctor in charge was given to the 21 
patients and their guardians in case they required advice or care outside normal working hours. 22 
During each monthly follow-up visit, the self-recorded health diaries were reviewed by the 23 
investigators. The data of each follow-up visit were entered by the same investigator in a paper 24 
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case report form (CRF) and electronic CRF, EpiData Software a comprehensive tool for 1 
validated entry and documentation of data. The EpiData Association, Odense, Denmark, 2003-2 
2005. 3 
Statistical analysis 4 
In a previous pilot study, it has been reported that treatment with combination of omega-3 and 5 
omega-6 fatty acids (Equazen™) resulted in ≥ 80% decrease in mean number of seizures over 6 
all subjects treated for four weeks [40]. Another pilot study using EPA only reported a 16%  7 
mean  reduction in seizure frequency26. Based on these pilot studies, it was assumed that 8 
treatment with either DHA or EPA would reduce annualized seizure incidence rate by 25% 9 
compared to the placebo group. To detect a 25% difference in annualized seizure incidence 10 
rate between the treatment groups and placebo groups with 85% power at a 5% significance 11 
and superiority margin equal to zero (δ = 0) to test for statistical superiority, twenty five (n=25) 12 
patients were required in each arm of the study. The total number of participating patients was 13 
increased to (n=99) to compensate for an anticipated 35% loss to follow-up. 14 
The data is presented as mean ± standard deviation (SD), median and percentile or median and 15 
inter-quartile range (IQR) as appropriate. The epileptic seizures were summarized as average 16 
number of seizures/ month and analyses were undertaken on intention-to-treat basis by 17 
including all of the randomized patients (n=99). To account for the repeated measures nature 18 
of the data and over-dispersion (variance greater than the mean), random-effects negative 19 
binomial regression models were fitted to model the patients’ total count of seizures per month. 20 
The treatment effects on seizure incidence rate ratio was tested after controlling for the 21 
covariate effects of gender, age, rate of seizure per week at enrollment, type of seizure  and 22 
number of AED combinations used at enrollment. Multiple imputation was used to account for 23 
missing data. Statistical differences of the continuous variables were evaluated using ANOVA, 24 
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and post hoc analysis when significance was indicated.  A p-value of 0.05 is considered 1 
significant. STATA statistical package (version 14) was used for analyses. 2 
 3 
Results 4 
One hundred sixty-five patients diagnosed with DRE were screened for eligibility and ninety-5 
nine who fulfilled the inclusion criteria were enrolled and assigned to receive either DHA, EPA 6 
or placebo. The number of subjects who received at least one dose of the assigned study 7 
medication (safety population) were eighty-seven, of those 29 received placebo, 30 received 8 
EPA and 28 received DHA. Fifty-nine patients completed the study (n=59).  The CONSORT 9 
flow chart of patient enrollment, randomization and patient disposition are shown in Figure 1. 10 
At baseline, there was no difference in mean age, weight, gender distribution, type of seizure, 11 
number of seizures per week, mean illness duration since epilepsy diagnosis and number and 12 
type of AEDs in use (Table 1), and clinical laboratory parameters (Table 2). The most frequent 13 
concomitant AEDs were sodium valproate, Lamotrigine, Carbamazepine and Clonazepam. The 14 
number of subjects stopped one or two AEDs post randomization was 9, 8 and 7 patients among 15 
those received placebo, EPA or DHA, respectively.  16 
The mean number of seizures per month of the EPA-treated, DHA-treated and placebo after  17 
12 months of treatment  were 9.7 ± 1.2, 11.7 ± 1.5 and 16.6 ± 1.5 respectively (Table 3, Figure 18 
2A). Age and gender, seizure type adjusted seizure incidence rate ratios (IRRs) of the EPA and 19 
DHA treated groups compared to placebo, the primary endpoint, were 0.67 (CI= 0.46-0.1, 20 
p=0.04, 33% reduction) in DHA-treated group and 0.61 (CI = 0.42-0.88, p= 0.01, 39% 21 
reduction) in EPA-treated group. There was no difference in IRR between the EPA and DHA 22 
groups (p=0.6) (Table 3, Figure 2B).  Responder rates were 10.3% and 3.0% higher in the EPA 23 
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treated and DHA treated groups compared to the placebo. Both treatment groups had a 1 
significantly higher number of seizure-free days compared to placebo (p<0.05).   2 
Safety and tolerability: 3 
No treatment-related adverse event occurred during the study period. Unrelated to treatment, 4 
there were 9 (30%), 4 (14 .3%) and 15 (51.7%) reported adverse events (AEs) in the EPA, 5 
DHA and placebo groups respectively. The most frequent AEs among those who received EPA 6 
or DHA were a decreased appetite, fever and rash. None of the treated patients developed 7 
epistaxis or mucosal bleeding.   8 
There were no differences in levels of hematological and liver function parameters between the 9 
EPA or DHA treated group and placebo after one year of intervention (Table 2).  10 
 11 
Discussion 12 
This study demonstrates that the treatment of patients with a history of drug-resistant epilepsy 13 
with a high EPA (EPA:DHA; 4.9:1) or a high DHA (EPA:DHA; 1:8.2) treatment in 14 
conjunction with a stable regimen of anti-epileptic drugs reduces significantly monthly seizure 15 
frequency. Consistent with these findings, efficacy was reported by Schlanger et al22  and  16 
DeGiorgio et al on those who  received a  low dose of  EPA & DHA21 . In contrast, Bromfield 17 
et al 15 and Yuen et al 14 did not find positive outcomes.  Differences in duration of the treatment 18 
period, dose of EPA and DHA and their ratios and/or dietary and genetic backgrounds of the 19 
participants might account for the conflicting findings. In the current study, the participants 20 
were treated with either DHA or EPA for 12 months.  21 
The dose used for this study was based solely on the previous evidence and observation 22 
generated out of the myriad of preclinical and few clinical studies, the US FDA Generally 23 
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Recognized as Safe (GRAS) omega-3 dose/ day (3 g/day) and the available data on DHA and 1 
EPA pharmacokinetics. The DHA and EPA doses investigated in this study are higher than the 2 
DHA and EPA combination used by Yuen et al and Bromfield et al and study14, 15, 21. Recently,  3 
DeGiorgio et al reported the results of the first well-powered RCT on the effect of low (1080 4 
mg EPA+DHA/day) and high doses (2160 mg EPA+DHA/day) in patients with DRE. Low 5 
dose omega-3 fatty acid was associated with a 33.6% reduction in seizure frequency compared 6 
with the placebo, whereas the high dose was not different than placebo. Interestingly, the 7 
reported 33% reduction in seizure rate among those received the low dose is similar to the 8 
finding we observed in the DHA group.   The lack of efficacy of the high dose of the EPA and 9 
DHA combination reported by DeGiorgio et al is intriguing.  One possible explanation that 10 
high dosages my result in excessive reduction in non-esterified fatty acids such as arachidonic 11 
acid21, 27.  12 
 In contrary to the DeGiorgio et al study results 21, the finding of this study does not show 13 
similar lack of efficacy of seemingly high DHA or EPA doses. The varied outcomes of these 14 
two studies could be a reflection of the EPA and DHA composition used in each study or the 15 
relatively short treatment and washout periods of the cross-over study design of DeGiorgio et 16 
al study28.  DHA is not readily released from neuronal membranes in adult mammals even if 17 
their diet is limited in the fatty acid 29. Therefore, one is unsure whether or not the washout 18 
period was sufficient to return neuronal DHA level to baseline in the study conducted by 19 
DeGiorgio et al.  Moreover, the wisdom of using linoleic acid (corn oil), the parent compound 20 
of arachidonic acid, which is pro-inflammatory, as a placebo control is questionable.  21 
DHA is the primary structural and functional fatty acid component of the brain cells, 22 
particularly the neurons30. EPA, which is found in small amounts in all of the brain cells, 23 
accounts for only about 0.1% total fatty acids31. Perhaps surprisingly, the treatment of various 24 
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neuropsychiatric conditions with pure EPA has been shown to be more effective than DHA 32, 1 
33.  These findings have led many to surmise pure EPA would more efficacious in reducing 2 
seizures in patients with DRE 14. In the current study, and in line with previous preclinical 3 
studies 34, 35, both the high EPA and high DHA supplements were effective in reducing seizures.  4 
The observed positive therapeutic effect of DHA and EPA on patients with DRE is consistent 5 
with animal models treated with EPA and DHA for long duration16-20.  Interestingly, a time-6 
course study conducted by Taha et al. showed that at least 3 months are required for DHA and 7 
EPA to raise seizure threshold36. The delayed effect of DHA and EPA was attributed to the 8 
slow process of enriching the neuronal tissues with these fatty acids, delay in formation of 9 
unestrified EPA and DHA or their bioactive metabolite such as protectins (NPD1)20.  10 
A dysfunction in the activity of voltage-gated sodium channels is thought to be central to the 11 
pathogenesis of epileptic seizures 37.  Indeed, most of the widely used antiepileptic drugs 12 
ameliorate seizures by acting on voltage-gated ion channels in patients with the condition38. 13 
There is evidence that polyunsaturated fatty acids modulate voltage-gated ion channels and 14 
neuronal excitation 8, 39. Xiao et al. made the seminal observation that EPA suppresses voltage-15 
activated Na+ currents in cultured rat myocyte and both EPA and DHA reduce inward calcium 16 
current, prolonging the inactivation state39.    It is hypothesized that these effects are dependent 17 
on the presence of two or more double bonds with a cis configuration 40. If this is the case, both 18 
EPA and DHA independently and/or in concert might reduce neuronal excitability and seizure 19 
rate.    20 
DHA and EPA were well tolerated with no clinically relevant laboratory changes during the 21 
study. Some preclinical studies have suggested that chronic intake of omega-3 fatty acids might 22 
result in excessive reactive oxygen species (ROS), which could contribute to brain aging. 23 
However, other preclinical and clinical studies found no effect or even reduction in ROS 24 
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production after chronic intake of high n-3 fatty acids. Further studies are needed to delineate 1 
the true long term effect of chronic treatment with high omega-3 fatty acids in patients with 2 
DRE. 3 
The main limitations of the study include: heterogeneity of the study population with regard to 4 
seizure frequency and type; reliance on patients reported seizure frequency data to assess the 5 
effects of the interventions; due to the study long duration some patients stopped one or two 6 
AED;  inability to determine markers of inflammation and oxidative stress because of financial 7 
constraints. The study was conducted in Sudanese patients whose traditional diet is low in n-3 8 
fatty acids. Therefore the findings may not be extrapolated to other patient populations with 9 
high omega-3 intake.  10 
In conclusion, this randomized, double-blind, placebo controlled study demonstrates that EPA 11 
or DHA is a safe and effective add-on therapy for patients with drug resistant epilepsy.  12 
  13 
Ibrahim et al 
15 
 
Acknowledgements  1 
Very sincere thanks are due to the patients and support staffs of the Epilepsy Referral Clinic, 2 
Soba University Hospitals and Ibn-Aoaf Pediatric Teaching Hospital (Sudan), and to Mr Peter 3 
Clough, Efamol Limited UK, for his expert advice and support throughout the duration of the 4 
study. Special Thanks go to Zawaya Group for sponsoring the study.  5 
  6 
Ibrahim et al 
16 
 
Authorship and Conflicts of Interest 1 
K.G. and A.D. conceived the idea, designed and initiated the study. K.G, A.D. M.E, A.A and 2 
F.I wrote the study protocol. A.D.; F.I. and M.A. developed the study questionnaires, Clinical 3 
Report Form (CRF) and coordinated the implementation of the trial. F.I., A.D.,I.G, A.A., M.A.; 4 
A.H.; M.S; G.O; and I.E. recruited, followed the patients and collected clinical data. F.I., Q.O, 5 
M.S Conducted laboratory analysis and data entry. A.D and M.A. developed the statistical 6 
analysis plan. M.A. and A.D. conducted the statistical analysis. A.D and F.I. interpreted the 7 
data. A.D wrote the first draft of the manuscript. F.I, M.E, K.G, M.A, AR, AA reviewed the 8 
manuscript and provided critical suggestion and comment. None of the authors disclosed a 9 
conflict of interest. AD and AR are currently employee of Sancilio Pharmaceuticals Company.  10 
The sponsors had no influence on the design of the study, collection, analysis and interpretation 11 
of data, writing of the manuscript or decision to submit for publication. 12 
  13 
Ibrahim et al 
17 
 
Ethical Publication Statement  1 
We confirm that we have read the journal’s position on issues involved in ethical publication 2 
and affirm that this report is consistent with those guidelines.  3 
 4 
 5 
6 
Ibrahim et al 
18 
 
References: 1 
1. Jensen, F.E., Epilepsy in 2013: progress across the spectrum of epilepsy research. Nat 2 
Rev Neurol, 2014; 10: 63-4. 3 
2. Panayiotopoulos, C.P., The new ILAE report on terminology and concepts for the 4 
organization of epilepsies: critical review and contribution. Epilepsia, 2012; 53: 399-5 
404. 6 
3. Ngugi, A.K., C. Bottomley, I. Kleinschmidt, et al., Estimation of the burden of active 7 
and life-time epilepsy: a meta-analytic approach. Epilepsia, 2010; 51: 883-90. 8 
4. Kwan, P., S.C. Schachter, and M.J. Brodie, Drug-resistant epilepsy. N Engl J Med, 9 
2011; 365: 919-26. 10 
5. Mitchell, J.W., S. Seri, and A.E. Cavanna, Pharmacotherapeutic and Non-11 
Pharmacological Options for Refractory and Difficult-to-Treat Seizures. J Cent Nerv 12 
Syst Dis, 2012; 4: 105-15. 13 
6. Fujita, S., Y. Ikegaya, M. Nishikawa, et al., Docosahexaenoic acid improves long-term 14 
potentiation attenuated by phospholipase A(2) inhibitor in rat hippocampal slices. Br J 15 
Pharmacol, 2001; 132: 1417-22. 16 
7. Vreugdenhil, M., C. Bruehl, R.A. Voskuyl, et al., Polyunsaturated fatty acids modulate 17 
sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci U S A, 1996; 93: 18 
12559-63. 19 
8. Elinder, F. and S.I. Liin, Actions and Mechanisms of Polyunsaturated Fatty Acids on 20 
Voltage-Gated Ion Channels. Front Physiol, 2017; 8: 43. 21 
9. Mitchell, D.C., S.L. Niu, and B.J. Litman, Enhancement of G protein-coupled signaling 22 
by DHA phospholipids. Lipids, 2003; 38: 437-43. 23 
Ibrahim et al 
19 
 
10. Zhang, W., J. Liu, X. Hu, et al., n-3 Polyunsaturated Fatty Acids Reduce Neonatal 1 
Hypoxic/Ischemic Brain Injury by Promoting Phosphatidylserine Formation and Akt 2 
Signaling. Stroke, 2015; 46: 2943-50. 3 
11. Calder, P.C., n-3 fatty acids, inflammation and immunity: new mechanisms to explain 4 
old actions. Proc Nutr Soc, 2013; 72: 326-36. 5 
12. Patrick, R.P. and B.N. Ames, Vitamin D and the omega-3 fatty acids control serotonin 6 
synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and 7 
impulsive behavior. FASEB J, 2015; 29: 2207-22. 8 
13. Taha, A.Y., Y. Cheon, K. Ma, et al., Altered fatty acid concentrations in prefrontal 9 
cortex of schizophrenic patients. J Psychiatr Res, 2013; 47: 636-43. 10 
14. Yuen, A.W., J.W. Sander, D. Fluegel, et al., Omega-3 fatty acid supplementation in 11 
patients with chronic epilepsy: a randomized trial. Epilepsy Behav, 2005; 7: 253-8. 12 
15. Bromfield, E., B. Dworetzky, S. Hurwitz, et al., A randomized trial of polyunsaturated 13 
fatty acids for refractory epilepsy. Epilepsy Behav, 2008; 12: 187-90. 14 
16. Taha, A.Y., W.M. Burnham, and S. Auvin, Polyunsaturated fatty acids and epilepsy. 15 
Epilepsia, 2010; 51: 1348-58. 16 
17. Voskuyl, R.A., M. Vreugdenhil, J.X. Kang, et al., Anticonvulsant effect of 17 
polyunsaturated fatty acids in rats, using the cortical stimulation model. Eur J 18 
Pharmacol, 1998; 341: 145-52. 19 
18. Xiao, Y. and X. Li, Polyunsaturated fatty acids modify mouse hippocampal neuronal 20 
excitability during excitotoxic or convulsant stimulation. Brain Res, 1999; 846: 112-21 
21. 22 
Ibrahim et al 
20 
 
19. Gavzan, H., M. Sayyah, S. Sardari, et al., Synergistic effect of docosahexaenoic acid 1 
on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models. 2 
Naunyn Schmiedebergs Arch Pharmacol, 2015; 388: 1029-38. 3 
20. DeGiorgio, C.M. and A.Y. Taha, Omega-3 fatty acids (-3 fatty acids) in epilepsy: 4 
animal models and human clinical trials. Expert Rev Neurother, 2016; 16: 1141-5. 5 
21. DeGiorgio, C.M., P.R. Miller, R. Harper, et al., Fish oil (n-3 fatty acids) in drug 6 
resistant epilepsy: a randomised placebo-controlled crossover study. J Neurol 7 
Neurosurg Psychiatry, 2015; 86: 65-70. 8 
22. Schlanger, S., M. Shinitzky, and D. Yam, Diet enriched with omega-3 fatty acids 9 
alleviates convulsion symptoms in epilepsy patients. Epilepsia, 2002; 43: 103-4. 10 
23. Estruch, R., E. Ros, J. Salas-Salvado, et al., Primary prevention of cardiovascular 11 
disease with a Mediterranean diet. N Engl J Med, 2013; 368: 1279-90. 12 
24. Purcell, R., S.H. Latham, K.M. Botham, et al., High-fat meals rich in EPA plus DHA 13 
compared with DHA only have differential effects on postprandial lipemia and plasma 14 
8-isoprostane F2alpha concentrations relative to a control high-oleic acid meal: a 15 
randomized controlled trial. Am J Clin Nutr, 2014; 100: 1019-28. 16 
25. Kromhout, D., E.J. Giltay, J.M. Geleijnse, et al., n-3 fatty acids and cardiovascular 17 
events after myocardial infarction. N Engl J Med, 2010; 363: 2015-26. 18 
26. Yuen, A.W., D. Flugel, A. Poepel, et al., Non-randomized open trial of 19 
eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic 20 
epilepsy. Epilepsy Behav, 2012; 23: 370-2. 21 
Ibrahim et al 
21 
 
27. Gilby, K.L., J. Jans, and D.C. McIntyre, Chronic omega-3 supplementation in seizure-1 
prone versus seizure-resistant rat strains: a cautionary tale. Neuroscience, 2009; 163: 2 
750-8. 3 
28. Mills, E.J., A.W. Chan, P. Wu, et al., Design, analysis, and presentation of crossover 4 
trials. Trials, 2009; 10: 27. 5 
29. Kim, H.Y., Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem, 6 
2007; 282: 18661-5. 7 
30. Crawford, M.A., C.L. Broadhurst, M. Guest, et al., A quantum theory for the 8 
irreplaceable role of docosahexaenoic acid in neural cell signalling throughout 9 
evolution. Prostaglandins Leukot Essent Fatty Acids, 2013; 88: 5-13. 10 
31. Chen, C.T., Z. Liu, M. Ouellet, et al., Rapid beta-oxidation of eicosapentaenoic acid in 11 
mouse brain: an in situ study. Prostaglandins Leukot Essent Fatty Acids, 2009; 80: 157-12 
63. 13 
32. Peet, M. and D.F. Horrobin, A dose-ranging study of the effects of ethyl-14 
eicosapentaenoate in patients with ongoing depression despite apparently adequate 15 
treatment with standard drugs. Arch Gen Psychiatry, 2002; 59: 913-9. 16 
33. Ross, B.M., J. Seguin, and L.E. Sieswerda, Omega-3 fatty acids as treatments for 17 
mental illness: which disorder and which fatty acid? Lipids Health Dis, 2007; 6: 21. 18 
34. El-Mowafy, A.M., M.A. Abdel-Dayem, A. Abdel-Aziz, et al., Eicosapentaenoic acid 19 
ablates valproate-induced liver oxidative stress and cellular derangement without 20 
altering its clearance rate: dynamic synergy and therapeutic utility. Biochim Biophys 21 
Acta, 2011; 1811: 460-7. 22 
Ibrahim et al 
22 
 
35. Abdel-Dayem, M.A., A.A. Elmarakby, A.A. Abdel-Aziz, et al., Valproate-induced 1 
liver injury: modulation by the omega-3 fatty acid DHA proposes a novel 2 
anticonvulsant regimen. Drugs R D, 2014; 14: 85-94. 3 
36. Taha, A.Y., M.O. Trepanier, F.A. Ciobanu, et al., A minimum of 3 months of dietary 4 
fish oil supplementation is required to raise amygdaloid afterdischarge seizure 5 
thresholds in rats--implications for treating complex partial seizures. Epilepsy Behav, 6 
2013; 27: 49-58. 7 
37. Kaplan, D.I., L.L. Isom, and S. Petrou, Role of Sodium Channels in Epilepsy. Cold 8 
Spring Harb Perspect Med, 2016; 6. 9 
38. Yogeeswari, P., J.V. Ragavendran, R. Thirumurugan, et al., Ion channels as important 10 
targets for antiepileptic drug design. Curr Drug Targets, 2004; 5: 589-602. 11 
39. Xiao, Y.F., A.M. Gomez, J.P. Morgan, et al., Suppression of voltage-gated L-type Ca2+ 12 
currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. 13 
Proc Natl Acad Sci U S A, 1997; 94: 4182-7. 14 
40. Yazdi, S., M. Stein, F. Elinder, et al., The Molecular Basis of Polyunsaturated Fatty 15 
Acid Interactions with the Shaker Voltage-Gated Potassium Channel. PLoS Comput 16 
Biol, 2016; 12: e1004704. 17 
 18 
 19 
Figure 1. Trial Flowchart of patients’ enrollment, randomization assignments and follow-up   
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Figure 2: A) Cumulative mean number of seizures in patients with drug resistant epilepsy treated with EPA, DHA or placebo. B) 
Adjusted seizure incidence rate ratios (IRRs) of the EPA or DHA treated compared with the placebo group.
Table 3 The effect of treatment with DHA or EPA on epileptic seizures in patients with drug resistant epilepsy
† Statistical significance assessed based on linear regression of total seizure by treatment group with multiple imputations (20 data sets).
†† Seizure incidence rate ratio as analyzed by negative binominal regression model. Statistical significance assessed based on intention-to-treat analysis with 
multiple imputations (20 data sets). 
††† Percentage of patients, with more than 9 month follow up, experiencing ≥50% reduction (response rate) in mean seizure compared with baseline. 
††† Statistical significance assessed based on logistic regression of number of seizure free days by treatment group with multiple imputations (20 data sets).
1P-value, DHA-treated versus placebo
2P-value, EPA-treated versus placebo
3P-value, DHA-treated versus EPA-treated 
 DHA group (n=33) EPA group (n=33) Placebo group (n=33)
 Measure 1p-value Measure 2p-value Measure 3p-value
EFFICACY MEASURE
Average number of seizure/month (mean 
± SE)†
11.7 ± 1.5 0.012 9.7 ± 1.2 0.001 16.6 ± 1.5 0.419
Seizure incidence rate ratio((IRR 
(Confidence interval))††
0.67
(0.46-1.0)
0.043
0.61
(0.42-0.88)
0.008 Ref=1 0.563
Seizure, percent change from placebo -30% -42% NA
Response rate††† 63.4% (n=14) 56.3% (n=16) 53.3% (n=15)
Mean number of seizure-free days †††† 23.1 <0.001 24.5 <0.001 19.9 0.097
Table 1 Demographic and clinical characteristics of the patients 
Placebo Group
(n=33)
EPA Treated 
Group
(n=33)
DHA Treated 
Group
(n=33)
Total
 No. % No. % No. % No. %
Gender
Male 19 57.6 22 66.7 22 66.7 63 63.6
Female 14 42.4 11 33.3 11 33.3 36 36.4
Total 33 100 33 100 33 100 99 100
Age (years)
Adult 18+ 3 9.1 6 18.2 5 15.2 14 14.1
Child <18 30 90.9 27 81.8 28 84.8 85 85.9
Total 33 100 33 100 33 100 99 100
Seizure type
Generalized 21 63.6 23 69.7 23 69.7 67 67.7
Focal 9 27.3 7 21.2 4 12.1 20 20.2
Unknown 3 18.2 3 6.1 6 9.1 11 11.1
Total 33 109.1 33 97 33 100 99 100
 Seizures per month at enrollment 
2-4 6 18.2 6 18.2 4 12.1 16 16.2
5-12 8 24.2 10 30.3 11 33.3 29 29.3
13-24 9 27.3 7 21.2 4 12.1 20 20.2
>24 6 18.2 7 21.2 8 24.2 21 21.2
Missing 4 12.1 3 9.1 6 18.2 13 13.1
Total 33 100 33 100 33 100 99 100
Drugs used at enrolment
Na valproate 26 78.8 23 69.7 27 81.8 76 76.8
Carbamezapin 9 27.3 8 24.2 10 30.3 27 27.3
Lamotrigine 18 54.5 18 54.5 7 21.2 43 43.4
Toprimate 1 3 4 12.1 4 12.1 9 9.1
Clonazepam 13 39.4 15 45.5 16 48.5 44 44.4
Phenobarbitone 1 3 4 12.1 2 6.1 7 7.1
Phenytoin 0 0 0 0 1 3 1 1
Levetiracetam 
(Keppra) 1 3 1 3 0 0 2 2
others 0 0 1 3 1 3 2 2
Number of drug combinations used at enrollment
2 20 60.6 16 48.5 21 63.6 57 57.6
3 10 30.3 14 42.4 8 24.2 32 32.3
≥4 3 9.1 3 9.1 4 12.1 10 10.1
Total 33 100 33 100 33 100 99 100
Table 2:   Hematological, lipid, glucose and liver enzyme profile of the patients with drug resistant epilepsy treated with DHA, EPA or 
placebo
Placebo group DHA-treated group EPA-treated group
Baseline 
(n=29)
Mean ± SE
One year 
(n=29)
Mean ± SE
Baseline 
(n=28)
Mean ± SE
One year 
(n=28)
Mean ± SE
Baseline 
(n=30)
Mean ± SE
One year 
(n=30)
Mean ± SE p-value 1* p-value 2**
Hematological 
White Blood Cells (WBCs) 6.2 ± 0.4 6.0 ± 0.4 6.0 ± 0.4 5.8 ± 0.5 6.3 ± 0.4 6.0 ± 0.5 0.323 0.949
Red Blood Cells (RBCs) 4.4 ± 0.1 4.2 ± 0.2 4.3 ± 0.1 4.3 ± 0.2 4.5 ± 0.1 4.5 ± 0.2 0.817 0.424
Haemoglobin (HGB) 11.2 ± 0.2 11.7 ± 0.4 11.1 ± 0.3 11.9 ± 0.5 11.5 ± 0.3 12.3 ± 0.5 0.016 0.740
Haematocrit (HCT) 37.1 ± 1.4 34.9 ± 1.5 36.3 ± 1.4 36.0 ± 1.5 36.7 ± 0.9 37.8 ± 1.5 0.683 0.444
Mean Corpuscular 
Volume (MCV) 80.8 ± 2.3 83.3 ± 1.2 82.6 ± 1.0 82.9 ± 1.0 81.3 ± 1.1 82.8 ± 1.1 0.071 0.229
Mean Corpuscular 
Haemoglobin (MCH) 26.2 ± 0.5 30.7 ± 3.0 26.1 ± 0.4 29.0 ± 2.2 25.7 ± 0.6 27.6 ± 2.1 0.039 0.623
Mean Corpuscular Hb 
Concentration (MCHC) 31.3 ± 0.3 30.4 ± 1.5 31.7 ± 0.3 31.1 ± 1.1 31.1 ± 0.3 31.8 ± 1.0 0.703 0.786
Platelet (PLT) 308.0 ± 17.5 287.7 ± 36.4 275.4 ± 18.3 258.6 ± 32.1 269.4 ± 15.6 291.7 ± 34.7 0.832 0.930
Lipid & Glucose  
Triglyceride mg/dl 72.6 ± 5.9 86.7 ± 13.7 71.3 ± 4.9 88.4 ± 14.8 70.2 ± 4.4 68.5 ± 11.4 0.24 0.876
Cholesterol mg/dl 135.6 ± 7.4 149.4 ± 9.9 124.2 ± 5.6 143.5 ± 8.1 128.0 ± 5.0 144.3 ± 7.2 0.001 0.562
HDL mg/dl 27.4 ± 1.7 38.2 ± 3.7 26.6 ± 2.3 35.1 ± 3.8 27.6 ± 1.9 39.4 ± 2.5 <0.001 0.640
LDL mg/dl 70.9 ± 5.0 80.9 ± 5.8 65.0 ± 3.8 76.4 ± 5.6 65.9 ± 4.2 79.8 ± 5.3 <0.002 0.849
Glucose mg/dl 75.9 ± 2.2 80.4 ± 3.8 70.8 ± 2.8 82.4 ± 4.7 73.6 ± 2.5 80.7 ± 4.1 0.006 0.237
Liver  Enzymes 
ALP 138.8 ± 15.7 139.4 ± 22.4 123.7 ±  17.1 134.3 ±  23.1 109.7 ± 14.9 133.3 ± 21.5 0.399 0.737
AST 8.9 ± 1.1 12.5 ± 1.7 8.3 ±  1.1 13.3 ±  1.7 9.1 ± 1.1 12.9 ± 1.5 <0.001 0.541
ALT 5.2 ± 0.6 7.9 ± 1.6 4.7 ±  0.7 7.1 ±  1.4 4.9 ± 0.7 7.6 ± 1.3 0.01 0.823
*P-value1: comparison of the combined group between baseline and after 1 year 
**p-value2: p-value for interaction between group and time (baseline & one year)  using mixed effect models adjusting for covariates (gender, age 
continuous, baseline seizer rate per week, number of drug   combinations used previously before  enrollment and number of drug combinations used 
previously at  enrollment) using xtmixed after multiple imputations (20 datasets)
